Russo, M.; De Rosa, M.A.; Calisi, D.; Consoli, S.; Evangelista, G.; Dono, F.; Santilli, M.; Granzotto, A.; Onofrj, M.; Sensi, S.L.
Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits. Int. J. Mol. Sci. 2022, 23, 11418.
https://doi.org/10.3390/ijms231911418
AMA Style
Russo M, De Rosa MA, Calisi D, Consoli S, Evangelista G, Dono F, Santilli M, Granzotto A, Onofrj M, Sensi SL.
Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits. International Journal of Molecular Sciences. 2022; 23(19):11418.
https://doi.org/10.3390/ijms231911418
Chicago/Turabian Style
Russo, Mirella, Matteo A. De Rosa, Dario Calisi, Stefano Consoli, Giacomo Evangelista, Fedele Dono, Matteo Santilli, Alberto Granzotto, Marco Onofrj, and Stefano L. Sensi.
2022. "Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits" International Journal of Molecular Sciences 23, no. 19: 11418.
https://doi.org/10.3390/ijms231911418
APA Style
Russo, M., De Rosa, M. A., Calisi, D., Consoli, S., Evangelista, G., Dono, F., Santilli, M., Granzotto, A., Onofrj, M., & Sensi, S. L.
(2022). Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits. International Journal of Molecular Sciences, 23(19), 11418.
https://doi.org/10.3390/ijms231911418